河北医学2013，Vol.19Issue(2)：224-226,3.DOI:10.3969/j.issn.1006-6233.2013.02.25
健择联合顺铂治疗晚期非小细胞肺癌84例疗效观察
Clinical Observation of Gemcitabine Plus Cisplatin in the Treatment of Advanced Non-small Cell Lung Cancer
顾兰兵 1卢勇1
作者信息
- 1. 江苏省大丰市第三人民医院内科,江苏,大丰,224100
- 折叠
摘要
Abstract
Objective: To observe and evaluate the therapeutic effects and toxicity reaction of gemcit-abine plus cisplatin in the treatment of advanced non-small cell lung cancer ( NSCLC ). Method: Enrolled from May 2006 to Oct. 2009, 84 patients with advanced NSCLC were treated with gemcitabine plus cisplatin therapy. Gemcitabine 1000mg/m2 by intravenous infusion on 1st and 8th day, and cisplatin 40mg/m2 by intravenous infusion on 1-3th day in a 21-day cycle, and every patient was treated 2-3 cycles. Result: Of the 84 patients, 2 cases got complete response, 36 cases got partial response, with an overall response rate of 45. 24%. And the response rate was 51. 85% in patients of Ⅲb stage, 33. 33% in patients of IV stage; it was 55.56% in patients with squamous-celled NSCLC and 37.5% in patients with adenocarcinoma; it was 53. 57% in the initial patients and 28. 57% in the retreated patients. The main toxicities were bone marrow suppression and gastrointestinal tract reaction, and no bleeding or hepatic/renal function impairment was observed. Conclusion: The combination of gemcitabine and cisplatin is feasible, well-tolerated and effective scheme in advanced NSCLC patients.关键词
健择/顺铂/晚期非小细胞肺癌/化疗Key words
Gemcitabine/ Cisplatin/ Non-small cell lung cancer/ Chemotherapy引用本文复制引用
顾兰兵,卢勇..健择联合顺铂治疗晚期非小细胞肺癌84例疗效观察[J].河北医学,2013,19(2):224-226,3.
